Wonvas-F Tablet is a combination medication containing Fenofibrate 160 mg and Rosuvastatin 10 mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Fenofibrate, a fibric acid derivative, primarily acts by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles, thereby reducing serum triglycerides and increasing high-density lipoprotein cholesterol (HDL-C). Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) by inhibiting the rate-limiting enzyme in cholesterol biosynthesis. The combination therapy offers a synergistic effect in improving lipid profiles, reducing total cholesterol, LDL-C, triglycerides, and increasing HDL-C levels, thus aiding in the prevention of cardiovascular events in patients with mixed dyslipidemia who require multiple lipid-lowering agents. Wonvas-F is typically prescribed as an adjunct to diet and lifestyle modifications, including exercise and weight control. It is contraindicated in patients with active liver disease, severe renal impairment, or hypersensitivity to its components. Regular monitoring of liver function tests, renal parameters, and lipid levels is recommended during therapy. Caution should be exercised to avoid potential adverse effects such as myopathy and hepatotoxicity.